Table 2.
Adjusted* odds ratios (95% Confidence Intervals) for prostate cancer active therapy versus conservative management stratified by risk† in men ≥75 years with localized prostate cancer, SEER-Medicare (2004–2005)
| Characteristic | All (n = 8,323) | Low Risk (n=2,069) |
|---|---|---|
| Demographic: | ||
|
| ||
| Age (yrs) | 0.92 (0.91, 0.94) | 0.91 (0.88, 0.93) |
| Race | ||
| Black | 0.57 (0.47, 0.68) | 0.76 (0.52, 1.12) |
| Other | 1.34 (1.07, 1.66) | 1.33 (0.90, 1.97) |
| White | 1.00 | 1.00 |
|
| ||
| Non-Clinical: | ||
|
| ||
| Percent Below Poverty Line‡ | ||
| High | 0.97 (0.86, 1.09) | 0.99 (0.80, 1.22) |
| Low | 1.00 | 1.00 |
| Marital Status | ||
| Married | 1.37 (1.19, 1.58) | 1.19 (0.92, 1.55) |
| Unknown | 0.73 (0.61, 0.89) | 0.54 (0.38, 0.77) |
| Unmarried§ | 1.00 | 1.00 |
| Residency | ||
| Rural | 0.94 (0.76, 1.17) | 1.13 (0.76, 1.68) |
| Urban | 1.00 | 1.00 |
| Registry Region/City|| | ||
| Northeast | 1.74 (1.44, 2.09) | 2.41 (1.75, 3.32) |
| North Central | 1.61 (1.30, 1.99) | 1.83 (1.27, 2.64) |
| South | 1.09 (0.90, 1.32) | 1.41 (1.00, 1.99) |
| LA and SF | 0.87 (0.72, 1.05) | 1.13 (0.82, 1.57) |
| Other West | 1.24 (1.01, 1.53) | 1.45 (1.01, 2.08) |
| Greater CA and SJ | 1.00 | 1.00 |
|
| ||
| Clinical: | ||
|
| ||
| PSA (ng/mL) | ||
| 0.1– ≤4 | 0.82 (0.65, 1.04) | 0.95 (0.73, 1.25) |
| 4 – ≤ 10 | 0.89 (0.75, 1.05) | 1.00 |
| 10 – ≤ 20 | 1.21 (1.00, 1.47) | --- |
| >20 | 1.00 | --- |
| Gleason Score | ||
| 2–4 | 0.34 (0.44, 1.63) | 0.86 (0.45, 1.66) |
| 5–6 | 0.40 (0.36, 0.45) | 1.00 |
| 7–10 | 1.00 | |
| Tumor Stage | ||
| T1 | 0.93 (0.83, 1.05) | 1.35 (1.09, 1.66) |
| T2 | 1.00 | 1.00 |
| Charlson Comorbidity¶ | ||
| 2+ | 0.87 (0.73, 1.05) | 1.19 (0.84, 1.68) |
| 1 | 1.01 (0.87, 1.17) | 0.98 (0.76, 1.27) |
| 0 | 1.00 | 1.00 |
Adjusted for other variables in the model.
Patients were categorized into low risk group on the basis of clinical classification, PSA level and Gleason score: low-risk (T1–T2a and PSA level <10 ng/mL and Gleason score 2–6).
Percent of residents living below poverty level was obtained from the 2000 Census tracts and dichotomized at the median = 6.47%.
Other = Separated, Divorced, or Widowed
The Western registries were divided into three groups based on similar odds of receiving prostate cancer active therapy vs. conservative management in unadjusted analyses. Group 1: Other West = Utah, Seattle, New Mexico, and Hawaii; Group 2: Los Angeles (LA) and San Francisco (SF); and Group 3: San Jose (SJ) and Greater California (CA) (excluding San Francisco, Los Angeles, and San Jose-Monterey)